Inizio Evoke’s CMO Matthew Hoelzle on Medical Strategy, AI and Real-World Impact at ASCO 2025
Join Matthew Hoelzle, MD, Chief Medical Officer at Inizio Evoke, as he shares his insights from ASCO 2025 and discusses how Inizio—the world’s largest healthcare commercialization platform—is transforming oncology strategy across the entire drug lifecycle.
From early-stage molecule development to late-stage lifecycle management, Inizio partners with pharmaceutical companies of all sizes to drive innovation, brand differentiation, and patient-centered impact. Dr. Hoelzle highlights the key themes emerging at ASCO this year, including:
- Actionable clinical data with real-life patient impact
- The growing role of AI in early detection and biomarker discovery
- Creative solutions to challenges in clinical trial recruitment
- The shift toward integrating patient-reported outcomes in value frameworks
He also dives into Inizio Evoke’s approach to medical strategy, emphasizing adaptability, integrated stakeholder engagement, and the importance of balancing science with empathy. The conversation explores how pharma can evolve to meet changing definitions of value, improve global health outcomes, and maintain human connection in an increasingly digital age.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023